Note: chlorcyclizine is an antihistamine used to treat allergies, cough, and nasal congestion.
patients with chronic hepatitis C virus (HCV), chlorcyclizine HCl plus ribavirin showed some anti-HCV effects, according to results published in Antiviral Research.
The results indicated that the dose used in the study may be subtherapeutic in humans, and the researchers recommend further studies with different iterations of chlorcyclizine HCl.
The study included participants with chronic HCV (n=24). Participants were randomly assigned to receive chlorcyclizine HCl (75 mg twice daily) or chlorcyclizine HCl plus weight-based ribavirin (1000/1200 mg daily) for 28 days. Participants began therapy with a loading dose of chlorcyclizine HCl 150 mg ± ribavirin. The researchers performed serial assessments of safety, pharmacokinetic markers, and viral kinetic markers and did liver testing.
At the end of therapy, participants treated with chlorcyclizine HCl monotherapy did not have a significant or sustained reduction in viremia (P =.69). However, 58% (7/12) of those treated with chlorcyclizine HCl + ribavirin had a >3-fold decline in HCV RNA.